Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Authors: Meletios Dimopoulos, David S Siegel, Sagar Lonial, Junyuan Qi, Roman Hajek, Thierry Facon, Laura Rosinol, Catherine Williams, Hilary Blacklock, Hartmut Goldschmidt, Vania Hungria, Andrew Spencer, Antonio Palumbo, Thorsten Graef, Joseph E Eid, Jennifer Houp, Linda Sun, Scott Vuocolo, Kenneth C Anderson
Institutions: National and Kapodistrian University of Athens, Hackensack University Medical Center, Emory University, Winship Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, University of Ostrava, University Hospital Brno, Hôpital Claude Huriez, Hospital Clínic de Barcelona, Nottingham University Hospitals NHS Trust, Middlemore Hospital, University Hospital Heidelberg, The Alfred Hospital, Monash University, University of Turin, Merck & Co., Inc., Rahway, NJ, USA (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2104244233
